|
|
Article: TransMolecular Presents Imaging and Pharmacokinetic Analysis of (131)Iodine-TM601 at Society for Nuclear Medicine Meeting.
- Article from:
- Business Wire
- Article date:
- June 17, 2008
|
Copyright informationCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, Mass. -- TransMolecular, Inc., a biotechnology company focused on targeted therapies for cancer, today announced the presentation of an imaging and pharmacokinetic analysis of intravenous 131I-TM601 in patients with primary malignant glioma or solid tumor metastases. The abstract was discussed in an oral presentation at the Society for Nuclear Medicine's 55th Annual Meeting on June 16, 2008 by investigators at Northwestern Memorial Hospital and Northwestern University Feinberg School of Medicine.
Pharmacokinetic analysis revealed that 131I-TM601 rapidly clears from the blood stream and is then quickly removed from the body through the urinary system. ...